Drugs / NPI-001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial · 1 missed | ||||||
| Phase 1/2 | NCT04355689 | Sep 2020 → Jun 2025 | Usher syndrome | Nacuity Pharmaceuticals, Inc. | Completed | Missed primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT07710196 | Aug 2026 → Feb 2029 expected | Usher syndrome, retinitis pigmentosa | Nacuity Pharmaceuticals, Inc. | Not yet recruiting | No outcome recorded |
Press releases naming this drug 6 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NPI-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07710196 ↗ |
| Route | Oral | “oral tablet” NCT04355689 ↗ |